– USA, MA – Atalanta Therapeutics, a biotechnology company pioneering new treatment options for CNS diseases utilizing its proprietary branched siRNA platform, today announced the appointment of Dr. Al Sandrock (M.D., Ph.D.) to its Board of Directors.
About Dr. Alfred W. Sandrock, Jr.
Dr. Sandrock spent 23 years at Biogen where he served in positions of increasing responsibility, culminating in his service as EVP, research and development, until December 2021. He also served an eight-year term as the CMO, from 2012 to 2020, and on the Biogen Executive Committee, from 2013 to 2021. Earlier in his career, Dr. Sandrock held several senior executive positions at Biogen, including group SVP of development sciences, SVP of neurology R&D, and VP of clinical development, neurology. Throughout his tenure, he led the discovery, development, and regulatory approval of numerous medicines including Aduhelm, Plegridy, Spinraza, Tecfidera, and Tysabri.
“RNA interference is an exciting therapeutic approach, but its utility in neurological diseases has been limited by the difficulty in achieving the appropriate distribution in the central nervous system. Atalanta’s novel branched siRNA platform has the potential to overcome the challenges in developing therapies for CNS disorders. I’m pleased to join the company’s Board of Directors to help realize the promise of this exciting platform,” said Dr. Sandrock.
Dr. Sandrock holds a B.A. in human biology from Stanford University, an M.D. from Harvard Medical School, and a Ph.D. in neurobiology from Harvard University. He completed an internship in medicine, a residency and chief residency in neurology, and a clinical fellowship in Neuromuscular Disease and Clinical Neurophysiology (electromyography) at Massachusetts General Hospital.
About Atalanta Therapeutics
Atalanta Therapeutics is a biotechnology company pioneering new treatment options for neurodegenerative diseases by utilizing its proprietary RNA interference platform, branched siRNA, which for the first time enables RNA interference to be deployed as a therapeutic approach throughout the brain and spinal cord. Atalanta was founded in 2018 by Anastasia Khvorova, Ph.D., Craig Mello, Ph.D., and Neil Aronin, M.D., of the RNA Therapeutics Institute at the University of Massachusetts Medical School, with a Series A funding exclusively by F-Prime Capital and strategic collaborations with Biogen and Genentech. Atalanta is headquartered in Boston, Mass.
For more information: https://www.atalantatx.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
